New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:35 EDTALXNAlexion says data confirm long-term safety, efficacy of chronic Soliris therapy
Alexion Pharmaceuticals announced the presentation of new data demonstrating the long-term benefits of Soliris in patients with paroxysmal nocturnal hemoglobinuria, a debilitating, ultra-rare and life-threatening blood disorder. Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome were presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. The company said ten-year data from a large cohort of patients with PNH from the United Kingdom confirm the long-term safety and efficacy of chronic Soliris therapy and demonstrate the impact of Soliris on quality of life. The long-term safety of Soliris was also demonstrated in PNH clinical development trials in which patients were treated continuously with Soliris and followed for up to 5.5 years and other Soliris data was presented as well.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 18, 2014
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information
November 10, 2014
15:54 EDTALXNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTALXNJPMorgan biotech analyst to hold an analyst/industry conference call
U.S. SMid Biotech Analyst Rama, along with Key Opinion Leader Dr. Hickman Simmons from Vanderbilt University, discuss Alexion Pharmaceuticals' Asfotase Alfa and Hypophosophatasia on an Analyst/Industry conference call to be held on November 11 at 11 am.
06:31 EDTALXNAlexion announces planned retirement of co-founder, COO Stephen Squinto
Alexion announced the planned retirement of company co-founder Stephen Squinto, effective January 1, 2015. Squinto currently serves as Executive Vice President, Chief Global Operations Officer. He co-founded Alexion in 1992 with Leonard Bell, M.D., the Company’s principal founder and current Chairman and Chief Executive Officer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use